

Supplementary Table 3. Patient demographics, baseline characteristics and clinical response by exposure to anti-TNF α therapy: (A) RNA-seq Analysis Set; (B) Biomarker Analysis Set

A

Metric*	FIL			PBO		
	aTNFexpr (N=37)	aTNFnaïve (N=35)	P-value [†]	aTNFexpr (N=18)	aTNFnaïve (N=11)	P-value [†]
AGE	36 [29.0,42.0]	38 [29.5,41.5]	0.657	40 [32.3,44.0]	28 [24.0,31.5]	< 0.001
Sex (%)	F (64.9%), M (35.1%)	F (48.6%) M (51.4%)	0.163	F (66.7%) M (33.3%)	F (72.7%) M (27.3%)	0.732
Oral corticosteroids use, n (%)	16 (43.2%)	17 (48.6%)	0.65	11 (61.1%)	7 (63.6%)	0.892
CRP(mg/L)	8.9 [3.1,16.8]	7.4 [2.3,16.6]	0.164	5.5 [3.8,20.3]	3.6 [0.9,8.1]	0.381
CRP>10mg/L, n(%)	16 (43.2%)	13 (37.1%)	0.598	6 (33.3%)	2 (18.2%)	0.376
Disease duration (years)	8.1 [4.3, 13.8]	4.5 [2.0,9.5]	0.02	7.5 [4.2,10.4]	2.1 [1.0,5.5]	0.024
SESCD	13 [10.0,20.0]	11 [9.0,15.5]	0.233	15 [12.3, 20.3]	15 [12.5, 20.0]	0.891
Endoscopic response, n (%)	13 (37.1%)	10 (28.6%)	0.445	2 (11.1%)	2 (18.2%)	0.592
Anti-TNF α failed	35 (94.6%)	-	-	18 (100.0%)	-	-

* Values are median [Q1, Q3] unless stated otherwise

[†]P-values were generated by comparing means of the anti-TNF-experienced and anti-TNF-naïve data subsets. One-way ANOVA was used for continuous variables and Chi-Square test was used for categorical variables

B

Metric*	FIL			PBO		
	aTNFexpr (N=73)	aTNFnaïve (N=53)	P-value [†]	aTNFexpr (N=26)	aTNFnaïve (N=16)	P-value [†]
AGE	36 [29.0,42.0]	39 [29.0,48.0]	0.208	35 [28.0,43.3]	29.5 [25.8,34.5]	0.194
Sex (%)	F (60.3%) M (39.7%)	F (49.1%) M (50.9%)	0.211	F (53.8%) M (46.2%)	F (68.8%) M (31.2%)	0.339
Oral corticosteroids use, n (%)	38 (52.1%)	27 (50.9%)	0.902	14 (53.8%)	8 (50.0%)	0.808
CRP(mg/L)	8.9 [3.7,19.1]	6.6 [2.0,16.3]	0.41	15.4 [5.2,30.9]	7.0 [1.8,9.9]	0.05
CRP>10mg/L, n(%)	33 (45.2%)	21 (39.6%)	0.532	14 (53.8%)	4 (25.0%)	0.067
Disease duration (years)	7.9 [4.6,13.3]	3.6 [1.2,6.5]	< 0.001	6.5 [4.0,10.5]	2.7 [0.8,4.9]	0.007
SESCD	14 [10.0,20.0]	11 [9.0,15.0]	0.053	14 [11.3, 21.0]	15.5 [10.8,22.2]	0.72
Endoscopic response, n (%)	18 (30.0%)	13 (29.5%)	0.96	3 (15.0%)	3 (21.4%)	0.628

Anti-TNFa failed	69 (94.5%)	-	-	26 (100.0%)	-	-
-------------------------	------------	---	---	-------------	---	---

* Values are median [Q1, Q3] unless stated otherwise

†P-values were generated by comparing means of the anti-TNF-experienced and anti-TNF-naïve data subsets. One-way ANOVA was used for continuous variables and Chi-Square test was used for categorial variables